Events and Presentations

Corporate Presentation
Pipeline Program Detail
Scientific & Medical Meetings
November 15, 2021
Source
mRNA Encoding VEGF-A in Patients Undergoing Coronary Artery Bypass Grafting: Results of the Phase 2a EPICCURE Clinical Trial
November 12, 2021
Source
Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding huOX40L, IL-23, and IL-36γ Intratumoral (iTu) Injection +/- Durvalumab in Advanced Solid Tumors and Lymphoma
March 2, 2021
Source
Preliminary safety, antitumour activity and pharmacodynamic results of the Human Intratumoral Immunotherapy (HIT-IT) trial of MEDI1191 (mRNA IL-12) in patients with advanced solid tumours and superficial lesions
November 11, 2020
Source
A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors
August 26, 2020
May 29, 2020
Source
A Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral (iTu) Injection Alone and in Combination with Durvalumab
May 29, 2020
Source
A Phase 1 Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral (iTu) Injection Alone and in Combination with Durvalumab
April 27, 2020
Source
A Phase 1/2, Open Label, Multicenter, Dose Escalation and Efficacy Study of mRNA 2416, A Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection Alone or in Combination with Durvalumab for Patients with Advanced Malignancies
October 16, 2019
Source
mRNA Medicines to Enable Intracellular, Membrane-Bound, and Extracellular Secreted Therapeutics
October 2, 2019
Source
Phase 1 Trial of an mRNA-based Combination Vaccine Against hMPV and PIV3